Tebivudine as pre-emptive treatment against hepatitis B virus reactivation in patients after chemotherapy

Tian Wenguang; Wan Keqiang; He Ping; Li Wei; Ding Jing; Wei Xiaoyu; Huang Wenxiang

doi:10.13406/j.cnki.cyxb.000790

您当前的位置：

首页 >

文章列表页 >

Tebivudine as pre-emptive treatment against hepatitis B virus reactivation in patients after chemotherapy

更新时间：2024-01-17

- Tebivudine as pre-emptive treatment against hepatitis B virus reactivation in patients after chemotherapy
- Journal of Chongqing Medical University Vol. 40, Issue 11, Pages: 1454-1457(2015)
- 作者机构：
  
  1. 重庆医科大学附属永川医院感染科
  2. 重庆医科大学附属永川医院消化内科
  3. 重庆医科大学附属第一医院感染科
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.000790
  CLC： R512.62
- Published：2015，
扫描看全文
[1]田文广,万克强,何平,李伟,丁静,魏晓宇,黄文祥.替比夫定预防和治疗化疗后的乙肝病毒再激活临床疗效分析[J].重庆医科大学学报,2015,40(11):1454-1457.

Tian Wenguang, Wan Keqiang, He Ping, et al. Tebivudine as pre-emptive treatment against hepatitis B virus reactivation in patients after chemotherapy. [J]. Journal of Chongqing Medical University 40(11):1454-1457(2015)
[1]田文广,万克强,何平,李伟,丁静,魏晓宇,黄文祥.替比夫定预防和治疗化疗后的乙肝病毒再激活临床疗效分析[J].重庆医科大学学报,2015,40(11):1454-1457. DOI： 10.13406/j.cnki.cyxb.000790.

Tian Wenguang, Wan Keqiang, He Ping, et al. Tebivudine as pre-emptive treatment against hepatitis B virus reactivation in patients after chemotherapy. [J]. Journal of Chongqing Medical University 40(11):1454-1457(2015) DOI： 10.13406/j.cnki.cyxb.000790.

摘要

目的:评价替比夫定对化疗的乙肝病毒（hepatitis B virus

HBV）再激活的治疗效果及预防作用。方法:对照组为2006年1月至2009年12月的147例未使用替比夫定预防的化疗患者

观察接受化疗后乙肝病毒再激活情况、肝功能和临床表现。预防组为2010年1月至2012年12月的170例患者在化疗前1

周开始使用替比夫定

化疗后根据具体情况继续使用替比夫定6

2个月

观察HBV激活情况和临床表现。结果:317例患者在化疗期间共出现96例（30.3%）HBV再激活。对照组的147例患者

85例（57.8%）的患者出现HBV再激活

其中21例患者发展为重型肝炎

10例死亡;预防组的170例患者定期检测HBV Deoxyribonucleic acid（DNA）

有11例（6.5%）的患者出现HBV再激活（χ2=98.5

0.001）

2例发展为重型肝炎

1例死亡。结论:肿瘤合并非活动性HBV感染者化疗期间预防使用替比夫定可降低HBV再激活发生率

改善患者临床预后。

Abstract

Objective:To investigate the anti-virus therapy effect of tebivudine on HBV reactivation in malignant tumor patients with HBV infection after their cancer chemotherapy. Methods:Totally 317 malignant tumor patients with HBV infection receiving cytotoxic chemotherapy in the Yongchuan Hospital of Chongqing Medical University were enrolled in the study. The clinical characteristics of HBV replication and liver damage in control group from January 2006 to December 2009 without tebivudine were observed. Tebivudine was used 1-2 weeks in preventive group from Januanry 2010 to December 2012 before chemotherapy

and the duration lasted for 6-12 months according to patients’ compliance after completion of chemotherapy. The clinical manifestations about HBV reactivation were investigated at the same time. Results:Of all the 317 patients after chemotherapy

96 patients(30.3%)displayed HBV reactivation. Of the 147 patients in the control group

85 patients(57.8%)displayed HBV reactivation;21 patients developed liver failure

among them

10 patients died. While

of the 170 patients in the preventive group

only 11 patients(6.5%) suffered from HBV reactivation

2 patients developed liver failure

1 patient died. There were significant differences in ratio of HBV reactivation between prevention group and control group(P<0.001). Conclusion:Low incidence of HBV reaction will appear in non-active HBs Ag carriers in the preventive group during the use of tebivudine. Patients should use tebivudine in early phase to prevent HBV reactivation and to improve clinical prognosis.

关键词

乙肝病毒再激活化疗替比夫定

Keywords

hepatitis B virus(HBV)reactivationchemotherapytebivudine

references

Views

124

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research progress of breast cancer chemotherapy related HBV reactivation

Comparison of the clinical efficacy of Disitamab Vedotin and postoperative chemotherapy in the treatment of HER-2 positive locally advanced urothelial carcinoma

Effect of progressive muscle relaxation training on coping style and emotion of patients with lung cancer

ANTINEOPLASTIC DRUG SENSITIVITY TEST (MTT ASSAY) IN CHEMOTHERAPY OF GASTROINTESTINAL MALIGNANCY-A REPORT ON PRELIMINARY CLINICAL APPLICATION

The combined chemotherapy of ifosfamide plus vindesine and cisplatin in advanced non-small cell lung cancer

Related Author

Dong Lin

Zeng Aizhong

Xu Qiao

Jiang Yu

Wan Shihao

He Yunfeng

Zhang Xia

Zhang Jingping

Related Institution

Department of Infectious Diseases,The First Affiliated Hospital of Chongqing Medical University

Department of Urology，The First Affiliated Hospital of Chongqing Medical University

Department of Clinic Nursing,Xiangya Nursing School of Central South University

重庆医科大学肿瘤病理生理研究室

重庆医科大学第一医院普外科

⁰